FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064814731> ?p ?o ?g. }

• W2064814731 endingPage "e60145" @default.
• W2064814731 startingPage "e60145" @default.
• W2064814731 abstract "Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers including medulloblastoma, glioblastoma, melanoma as well as pancreas, colorectal, and prostate carcinomas. Here we investigated the role of the transcription factor Gli1 in ovarian cancer. To this end, the expression profile of Gli1 was examined in normal ovaries, ovarian tumors, and ovarian cancer cell lines, and the in vitro effects of a specific Hh-pathway blocker, KAAD-cyclopamine, or a specific Gli1 inhibitor (GANT58) on cell proliferation and on Hh target gene expression were also assessed. Results obtained showed that epithelial cells in ovarian cancer tissue express significantly higher levels of nuclear Gli1 than in normal ovarian tissue, where the protein was almost undetectable. In addition, multivariate analysis showed that nuclear Gli1 was independently associated to poor survival in advanced serous ovarian cancer patients (HR = 2.2, 95%CI 1.0–5.1, p = 0.04). In vitro experiments demonstrated Gli1 expression in the three ovarian carcinoma cell lines tested, A2780, SKOV-3 and OVCAR-3. Remarkably, although KAAD-cyclopamine led to decreased cell proliferation, this treatment did not inhibit hedgehog target gene expression in any of the three ovarian cancer cell lines, suggesting that the inhibition of cell proliferation was a nonspecific or toxic effect. In line with these data, no differences on cell proliferation were observed when cell lines were treated with GANT58. Overall, our clinical data support the role of Gli1 as a prognostic marker in advanced serous ovarian cancer and as a possible therapeutic target in this disease. However, our in vitro findings draw attention to the need for selection of appropriate experimental models that accurately represent human tumor for testing future therapies involving Hh pathway inhibitors." @default.
• W2064814731 created "2016-06-24" @default.
• W2064814731 creator A5001973740 @default.
• W2064814731 creator A5023052227 @default.
• W2064814731 creator A5023672805 @default.
• W2064814731 creator A5026048739 @default.
• W2064814731 creator A5042964644 @default.
• W2064814731 creator A5060930954 @default.
• W2064814731 creator A5071374096 @default.
• W2064814731 creator A5081853149 @default.
• W2064814731 date "2013-03-28" @default.
• W2064814731 modified "2023-09-30" @default.
• W2064814731 title "Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival" @default.
• W2064814731 cites W1964736695 @default.
• W2064814731 cites W1968530765 @default.
• W2064814731 cites W1998258610 @default.
• W2064814731 cites W2002126698 @default.
• W2064814731 cites W2012333247 @default.
• W2064814731 cites W2012462812 @default.
• W2064814731 cites W2018476741 @default.
• W2064814731 cites W2022532937 @default.
• W2064814731 cites W2030199762 @default.
• W2064814731 cites W2042753965 @default.
• W2064814731 cites W2044965556 @default.
• W2064814731 cites W2047272214 @default.
• W2064814731 cites W2047680962 @default.
• W2064814731 cites W2050425010 @default.
• W2064814731 cites W2087898777 @default.
• W2064814731 cites W2091609427 @default.
• W2064814731 cites W2093518370 @default.
• W2064814731 cites W2104892374 @default.
• W2064814731 cites W2106787323 @default.
• W2064814731 cites W2108261167 @default.
• W2064814731 cites W2110321605 @default.
• W2064814731 cites W2111826622 @default.
• W2064814731 cites W2121724128 @default.
• W2064814731 cites W2123226286 @default.
• W2064814731 cites W2124331403 @default.
• W2064814731 cites W2127247587 @default.
• W2064814731 cites W2128170361 @default.
• W2064814731 cites W2128801071 @default.
• W2064814731 cites W2128868545 @default.
• W2064814731 cites W2136753100 @default.
• W2064814731 cites W2140350596 @default.
• W2064814731 cites W2145447734 @default.
• W2064814731 cites W2161566367 @default.
• W2064814731 cites W2171027019 @default.
• W2064814731 cites W2257288579 @default.
• W2064814731 cites W2474599166 @default.
• W2064814731 doi "https://doi.org/10.1371/journal.pone.0060145" @default.
• W2064814731 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3610749" @default.
• W2064814731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23555905" @default.
• W2064814731 hasPublicationYear "2013" @default.
• W2064814731 type Work @default.
• W2064814731 sameAs 2064814731 @default.
• W2064814731 citedByCount "42" @default.
• W2064814731 countsByYear W20648147312013 @default.
• W2064814731 countsByYear W20648147312014 @default.
• W2064814731 countsByYear W20648147312015 @default.
• W2064814731 countsByYear W20648147312016 @default.
• W2064814731 countsByYear W20648147312017 @default.
• W2064814731 countsByYear W20648147312018 @default.
• W2064814731 countsByYear W20648147312019 @default.
• W2064814731 countsByYear W20648147312020 @default.
• W2064814731 countsByYear W20648147312021 @default.
• W2064814731 countsByYear W20648147312022 @default.
• W2064814731 countsByYear W20648147312023 @default.
• W2064814731 crossrefType "journal-article" @default.
• W2064814731 hasAuthorship W2064814731A5001973740 @default.
• W2064814731 hasAuthorship W2064814731A5023052227 @default.
• W2064814731 hasAuthorship W2064814731A5023672805 @default.
• W2064814731 hasAuthorship W2064814731A5026048739 @default.
• W2064814731 hasAuthorship W2064814731A5042964644 @default.
• W2064814731 hasAuthorship W2064814731A5060930954 @default.
• W2064814731 hasAuthorship W2064814731A5071374096 @default.
• W2064814731 hasAuthorship W2064814731A5081853149 @default.
• W2064814731 hasBestOaLocation W20648147311 @default.
• W2064814731 hasConcept C121608353 @default.
• W2064814731 hasConcept C142724271 @default.
• W2064814731 hasConcept C150173356 @default.
• W2064814731 hasConcept C2777605378 @default.
• W2064814731 hasConcept C2779933373 @default.
• W2064814731 hasConcept C2780427987 @default.
• W2064814731 hasConcept C502942594 @default.
• W2064814731 hasConcept C54355233 @default.
• W2064814731 hasConcept C62478195 @default.
• W2064814731 hasConcept C71924100 @default.
• W2064814731 hasConcept C86803240 @default.
• W2064814731 hasConcept C88498014 @default.
• W2064814731 hasConcept C95444343 @default.
• W2064814731 hasConceptScore W2064814731C121608353 @default.
• W2064814731 hasConceptScore W2064814731C142724271 @default.
• W2064814731 hasConceptScore W2064814731C150173356 @default.
• W2064814731 hasConceptScore W2064814731C2777605378 @default.
• W2064814731 hasConceptScore W2064814731C2779933373 @default.
• W2064814731 hasConceptScore W2064814731C2780427987 @default.
• W2064814731 hasConceptScore W2064814731C502942594 @default.
• W2064814731 hasConceptScore W2064814731C54355233 @default.

• next